+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05366179

Phase 1 Study of Intraventricular CAR-T Cell Therapy Targeting B7-H3 in Adults With Recurrent or Refractory Glioblastoma

Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-04-22

36

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment using T lymphocyte chimeric antigen receptor cells CAR.B7-H3T cells that target the B7-H3 antigen in adults with recurrent or refractory glioblastoma multiforme GBM. This phase 1 study focuses on testing the safety of this experimental therapy, which has not been previously tested in humans or approved by the Food and Drug Administration for glioblastoma. The study is conducted at a single center and is open-label, aiming to determine the safe dose levels through escalating doses. Eligible participants will have their cells collected during initial surgical resection to create the CAR.B7-H3T cells, ideally before starting adjuvant chemoradiation. When the glioblastoma recurs or becomes resistant, these specially manufactured CAR-T cells will be infused into the brains ventricles up to three times weekly through a Rickham catheter. Dose escalation will explore six dose levels starting at 2 million transduced cells per infusion, increasing if no severe toxicities occur. During the study, participants will be closely monitored for adverse events, including cytokine release syndrome and neurotoxicity, up to 10 weeks after treatment. Researchers will use MRI scans and clinical assessments to evaluate treatment safety and disease progression. The study also tracks longer-term outcomes such as progression-free survival and overall survival for up to five years. Participants must be willing and able to comply with all study procedures throughout the trial duration.

CONDITIONS

Brief Title

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

Research Team

C

Catherine Cheng

C

Caroline Babinec

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here